Successful surgical haemostasis in patients with von Willebrand disease with Koate®DVI

Haemophilia

Volumn 14, Issue 4, 2008, Pages 763-767

  Viswabandya, Auro ^a   Mathews, V ^a   George, B ^a   Nair, S C ^a   Baidya, S ^a   Mammen, J J ^a   Chandy, M ^a   Srivastava, A ^a  

^a CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

Koate DVI; Surgical haemostasis; Von Willebrand disease

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; KOATE DVI; VON WILLEBRAND FACTOR;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; HEMOSTASIS; HUMAN; MAJOR SURGERY; MINOR SURGERY; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; SURGICAL PATIENT; TREATMENT DURATION; VON WILLEBRAND DISEASE;

ADOLESCENT; ADULT; BLOOD LOSS, SURGICAL; CHILD; CHILD, PRESCHOOL; COAGULANTS; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FACTOR VIII; HEMOSTASIS, SURGICAL; HUMANS; MIDDLE AGED; PERIOPERATIVE CARE; TREATMENT OUTCOME; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR;

EID: 47649121204     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2008.01755.x     Document Type: Article

References (16)

1. Abshire TC. Prophylaxis and von Willebrand's disease (vWD). Thromb Res 2006; 118(Suppl 1): S3-S7.
2. Federici AB, Castaman G, Thompson A et al. Von Willebrand's disease: clinical management. Haemophilia 2006; 12(Suppl 3): 152-8.
3. Kaufmann JE, Vischer UM. Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP). J Thromb Haemost 2003; 1: 682-9.
4. Federici AB. Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: Results from current studies and surveys. Blood Coagul Fibrinolysis 2005; 16(Suppl 1): S17-S21.
5. Foster PA. On behalf of the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the ISTH. A perspective on the use of FVIII concentrates and cryoprecipitate prophylactically in surgery or therapeutically in severe bleeds in patients with von Willebrand disease unresponsive to DDAVP: Results of an international survey. Thromb Haemost 1995; 74: 1370-8.
6. Favaloro EJ, Koutts J. Laboratory assays for von Willebrand factor: relative contribution to the diagnosis of von Willebrand's disease. Pathology 1997; 29: 385-91.
7. Srivastava A, Mathews V, Bhurani D et al. Successful surgical hemostasis in patients with von Willebrand disease following infusion of KoateDVI. Thromb Haemost 2002; 87: 541-43.
8. Lethagen S, Kyrle PA, Castaman G et al. Von Willebrand factor/factor VIII concentrate (Haemate(R) P) dosing based on pharmacokinetics: A prospective multicenter trial in elective surgery. J Thromb Haemost 2007; 5: 1420-30.
9. Mannucci PM. Venous thromboembolism in von Willebrand disease. Thromb Haemost 2002; 88: 378-9.
10. Federici AB. Management of inherited von Willebrand disease in 2006. Semin Thromb Hemost 2006; 32: 616-20.
11. Nossent AY, Dai L, Rosendaal FR et al. Beta 2 adrenergic receptor polymorphisms: Association with factor VIII and von Willebrand factor levels and the risk of venous thrombosis. J Thromb Haemost 2005; 3: 405-7.
12. Lethagen S, Carlson M, Hillarp A. A comparative in vitro evaluation of six von Willebrand factor concentrates. Haemophilia 2004; 10: 243-9.
13. Shortt J, Dunkley A, Rickard K et al. Efficacy and safety of a high purity, double virus inactivated factor VIII/von Willebrand factor concentrate (Biostate®) in patients with von Willebrand disorder requiring invasive or surgical procedures. Haemophilia 2007; 13: 144-8.
14. Agrawal YP, Dzik W. The vWF content of factor VIII concentrates. Transfusion 2001; 41: 153-4.
15. Kasper CK, Brooker M. Registry of Clotting Factor Concentrates Vol. 6, 7th edn. World Federation of Haemophilia, 2006.
16. Slaby A, Pruthi RK, Wilke JL et al. Von Willebrand factor (vWF) concentrates: VWF multimer patterns, factor VIII and vWF content, and therapeutic efficacy. Haemophilia 2000; 6: 253.